Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge.
Keywords: Fragile X syndrome; arbaclofen; fragile X messenger ribonucleoprotein 1; neurodevelopmental conditions; phosphodiesterase; somatosensation.